Dr. Agarwal’s Health Care Ltd Q2FY26 – When the Eye Surgeon Becomes the Unicorn Surgeon (₹499 Cr Sales, ₹36 Cr PAT, P/E 141x, and Still No Dividend)
1. At a Glance
If “seeing is believing,” then Dr. Agarwal’s Health Care Ltd just turned every ophthalmologist into a believer — and every investor into a patient squinting at the P/E of 141. The ₹16,405 crore eye-care behemoth isn’t just the largest in India; it’s so dominant that its next competitor probably calls to ask for referrals.
In Q2FY26, the company reported revenue of ₹499 crore (up 19.7% YoY) and PAT of ₹36 crore (up 79% YoY). The operating margin strutted at 27%, with a return on capital employed of 9.99% and a humble ROE of 4.76%. The share trades at ₹519, giving a six-month return of 46.8% and making it the kind of stock that makes every retail investor say, “Yaar, thoda pehle dekhna chahiye tha.”
Market cap? ₹16,405 crore. Debt? ₹983 crore. Dividend? None — apparently, they believe in vision, not distribution. With 165 facilities across India and 15 more in Africa, Dr. Agarwal’s is now less of a hospital chain and more of an ophthalmic empire.
2. Introduction
You know how every Indian family has that one doctor who’s seen everyone’s eyes, from your grandfather’s cataract to your cousin’s myopia? Multiply that doctor by 258 facilities and a private equity cheque, and you get Dr. Agarwal’s Health Care Ltd — the doctor who IPO’d.
Founded in 2010 but carrying the legacy of the original Dr. Agarwal’s Eye Hospital, the company has spent the last decade turning vision correction into a scalable, profitable, and private-equity-approved business. In FY25, it clocked sales of ₹1,877 crore and PAT of ₹116 crore. The secret sauce? Leasing facilities, controlling capex, and operating with assembly-line efficiency — McDonald’s meets AIIMS.
The company boasts 737 doctors, over 1.15 million patients treated in H1FY25, and a clear obsession with lenses, lasers, and leverage. Despite all that, their ROE remains below 5%, proving that sometimes, 20/20 vision doesn’t guarantee financial clarity.
But make no mistake — this is not your neighborhood optician. It’s a full-blown institutional setup with centers of excellence, overseas operations, and a ₹3,000 crore IPO under its belt. Now the question is — are they eyeing expansion or just enjoying their reflection in the mirror?
3. Business Model – WTF Do They Even Do?
In plain sight (pun fully intended), Dr. Agarwal’s runs a three-tiered model that looks suspiciously like a well-managed multiplex for eyeballs.
Primary Facilities: The front-end — non-surgical clinics with optical counters and pharmacies. Think of them as diagnostic stalls at your nearest mall, minus the popcorn but plus a retina scan.
Secondary Facilities: The mid-tier setup — surgical centers performing cataract surgeries and basic clinical investigations. Essentially, this is where “my vision is blurry” becomes a ₹40,000 invoice.
Tertiary Facilities: The high-end super-specialty hospitals that handle complex retinal, corneal, or refractive surgeries. The company even operates three Centers of Excellence (COEs) for training and R&D, because what’s better than fixing eyes? Teaching others to do it for you.
Revenue-wise, 64% comes from surgeries and clinical services, 13% from optical products, and 8% from pharma items. Facilities older than three years contribute 76% of revenue, showing that new branches take time to mature — like whiskey, but more sterile.
Their model thrives on leases rather than ownership, keeping upfront costs low and allowing rapid expansion. Basically, they don’t buy land — they rent it, fill it with lasers, and call it “asset-light healthcare.” Genius, right?
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue (₹ Cr)
499
417
487
19.7%
2.5%
EBITDA (₹ Cr)
136
107
128
27.1%
6.3%
PAT (₹ Cr)
36
21
38
79.1%
-5.3%
EPS (₹)
0.94
0.54
0.95
74.0%
-1.1%
At an annualized EPS of ₹3.76, the P/E clocks in around 138x, which makes it costlier than Apollo’s hospital beds.
Margins stay steady at ~27%, showing operational consistency — or maybe just great billing. Revenue is on a steady rise, but PAT’s small size compared to the ₹16,000 crore market cap means the valuation lenses might need a power adjustment.
5. Valuation Discussion – Fair Value Range
Let’s play three ways to value an eye doctor:
a) P/E Method:
EPS (annualized): ₹3.76
Industry P/E: 59.6x
Fair Value Range = ₹3.76 × (60–90) = ₹225–₹340
b) EV/EBITDA Method:
EV = ₹17,199 crore
EBITDA (FY25 TTM) = ₹510 crore
EV/EBITDA = 33.7x If re-rated closer to peer median (20–25x), fair
